Thane Wettig
Director Ejecutivo en FIBROGEN, INC. .
Fortuna: 458 547 $ al 30/04/2024
Cargos activos de Thane Wettig
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| FIBROGEN, INC. | Director/Miembro de la Junta | 02/10/2023 | - |
| Director Ejecutivo | 23/07/2023 | - | |
| Corporate Officer/Principal | 22/06/2020 | 23/07/2023 |
Historial de carrera de Thane Wettig
Antiguos cargos conocidos de Thane Wettig.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| Lilly Diabetes | Corporate Officer/Principal | 01/01/1990 | 01/01/2009 |
| Ventas & Marketing | 01/01/2009 | - | |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01/01/2018 | - |
Formación de Thane Wettig.
| Washington University in St. Louis | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 5 |
Operativa
| Corporate Officer/Principal | 3 |
| Masters Business Admin | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
| Lilly Diabetes |
- Bolsa de valores
- Insiders
- Thane Wettig
- Experiencia